2018年国际妇产科联盟宫颈癌分期指南的预后效能
该研究利用美国国家癌症数据库纳入2004至2015年确诊的62212例宫颈癌女性,比较FIGO 2018、FIGO 2009及AJCC第7版分期的5年生存率区分能力。FIGO 2018将IB期按肿瘤大小分为IB1-IB3三个亚期,改善了区分度;但将所有淋巴结阳性患者归为IIIC期导致该组患者生存率高度异质。
要点
- FIGO 2018将IB期按肿瘤大小分为IB1、IB2、IB3三个亚期,提高了预后区分能力。
- FIGO 2018中IB1、IB2、IB3的5年生存率分别为91.6%、83.3%、76.1%。
- 将所有淋巴结阳性患者归为IIIC期导致该组生存率高度异质。
核心结论
- FIGO 2018分期对IB期肿瘤女性提供了改善的区分能力,但将所有淋巴结阳性女性归为单一分期导致患者群体高度异质且生存率差异很大。
研究设计与样本
- 利用美国国家癌症数据库识别2004至2015年确诊宫颈癌的女性,共62212例。
- 使用临床和病理数据,按AJCC第7版、FIGO 2009和FIGO 2018三种分期方案对每例患者进行分期。
- FIGO 2018将IB期肿瘤按大小分为IB1-IB3三个亚期,并将淋巴结阳性(病理或临床检测)患者归为IIIC1(盆腔淋巴结阳性)或IIIC2(腹主动脉旁淋巴结阳性)。
- 估计各分期组的5年生存率,以判断FIGO 2018是否较旧版分期提供更好的5年生存率区分。
主要发现
- FIGO 2018中IB1期肿瘤5年生存率为91.6%(95%CI 90.4-92.6%),IB2期为83.3%(95%CI 81.8-84.8%),IB3期为76.1%(95%CI 74.3-77.8%)。
- III期肿瘤中,FIGO分期较高并不一致地与更差的5年生存率相关:IIIA期为40.7%(95%CI 37.1-44.3%),IIIB期为41.4%(95%CI 39.9-42.9%),IIIC1期(盆腔淋巴结阳性)为60.8%(95%CI 58.7-62.8%),IIIC2期为37.5%(95%CI 33.3-41.7%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the prognostic performance of the revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging schema. METHODS: We used the National Cancer Database to identify women with cervical cancer diagnosed from 2004 to 2015. Using clinical and pathologic data, each patient's stage was classified using three staging schemas: American Joint Committee on Cancer 7th edition, FIGO 2009 and FIGO 2018. The FIGO 2018 revised staging classifies stage IB tumors into three substages based on tumor size (IB1-IB3) and classifies patients with positive lymph nodes (pathologically or clinically detected) as stage IIIC1 (positive pelvic nodes) or IIIC2 (positive para-aortic nodes). Five-year survival rates were estimated for each stage grouping. We sought to determine whether the 2018 FIGO staging system was able to offer improved 5-year survival rate differentiation compared with older staging schemas. RESULTS: A total of 62,212 women were identified. The classification of stage IB tumors into three substages improved discriminatory ability. Five-year survival in the FIGO 2018 schema was 91.6% (95% CI 90.4-92.6%) for stage IB1 tumors, 83.3% (95% CI 81.8-84.8%) for stage IB2 neoplasms, and 76.1% (95% CI 74.3-77.8%) for IB3 lesions. In contrast, for women with stage III tumors, higher FIGO staging was not consistently associated with worse 5-year survival rates: stage IIIA (40.7%, 95 CI 37.1-44.3%), stage IIIB (41.4%; 95% CI 39.9-42.9%), stage IIIC1 (positive pelvic nodes) was 60.8% (95% CI 58.7-62.8%) and stage IIIC2 37.5% (95% CI 33.3-41.7%). CONCLUSION: The FIGO 2018 staging schema provides improved discriminatory ability for women with stage IB tumors; however, classification of all women with positive lymph nodes into a single stage results in a very heterogeneous group of patients with highly variable survival rates.
引用
- Wright JD, Matsuo K, Huang Y, et al. Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. Obstet Gynecol. 2019. PMID: 31188324. doi:10.1097/AOG.0000000000003311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。